Table 3.
Minnesota GVHD risk score groups
| Standard risk | High risk | P | |
|---|---|---|---|
| N | 328 | 42 | |
| Age at transplant | 0.55 | ||
| Median (range), years | 7 (<1–17) | 8 (<1–17) | |
| Donor type | 0.20 | ||
| HLA-matched sibling donor | 57 (17%) | 4 (10%) | |
| Alternative donor | 271 (83%) | 38 (90%) | |
| Diagnosis | 0.39 | ||
| Malignancy | 172 (52%) | 25 (60%) | |
| Inborn errors of metabolism | 87 (27%) | 7 (17%) | |
| FA/AA/EB/Immune deficiency | 69 (21%) | 10 (24%) | |
| Organ involvement | <0.01 | ||
| Multi-organ | 33 (10%) | 17 (40%) | |
| Skin only | 245 (75%) | 5 (12%) | |
| Lower GI and upper GI | 13 (4%) | 5 (12%) | |
| Liver only | 0 | 3 (7%) | |
| Lower GI only | 14 (4%) | 12 (29%) | |
| Upper GI only | 23 (7%) | 0 | |
| Days to acute GVHD | <0.01 | ||
| Median (range) | 29 (8–100) | 36 (9–100) | |
| Days to chronic GVHD | 0.58 | ||
| Median (range) | 183 (50–1043) | 190 (84–892) | |
FA Fanconi anemia, AA Aplastic anemia, EB Epidermolysis bullosa